SCHEMBL20595705

SCHEMBL20595705

CCOC(=O)Cc1nc2cccc(-c3ccc(OC)cc3Cl)c2o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE7B Q9NP56 1/20 0.44
▸ CDC7 O00311 1/20 0.41
▸ DBF4 Q9UBU7 1/20 0.41
▸ PDE4B Q07343 1/20 0.41
▸ PDE4D Q08499 1/20 0.41
▸ PPARG P37231 1/20 0.41
▸ ALDH1A1 P00352 5/20 0.39
▸ HPGD P15428 4/20 0.39
▸ MAPT P10636 3/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ GAA P10253 3/20 0.39
▸ GLA P06280 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ CACNA1B Q00975 1/20 0.39
▸ APBA1 Q02410 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23419197 0.88 NR4A2 (0.41) KDM4EHSD17B10MEN1KMT2AMAPK1
SCHEMBL20595688 0.77 KDR (0.38) ALDH1A1MAPTMEN1KMT2AMAPK1
SCHEMBL20595726 0.73 SMN1; SMN2 (0.46) PDE7BALDH1A1KDM4EHSD17B10MEN1
SCHEMBL20595588 0.72 PDE4D (0.49) CDC7DBF4PDE4BPDE4DPPARG
SCHEMBL20596557 0.71 MAPT (0.43) CDC7DBF4PDE4BPDE4DPPARG
SCHEMBL16107363 0.71 TSHR (0.51) CDC7DBF4PPARGALDH1A1HPGD
SCHEMBL3425661 0.71 SMN1; SMN2 (0.43) PDE7BALDH1A1HPGDKDM4EHSD17B10
SCHEMBL30145197 0.71 MARS2 (0.45) ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL20595836 0.71 MARS2 (0.45) ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL20596512 0.69 F10 (0.44) CDC7DBF4PDE4BPDE4DPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 PDE7B 2492/4885CDC7 2772/4885DBF4 2130/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR PDE7B 2596/4885CDC7 2726/4885DBF4 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback